HealioAddition of rituximab to chemotherapy improved survival in follicular lymphomaHealioThe addition of rituximab to chemotherapy significantly improved OS among patients with follicular lymphoma, according to results of multiple trials presented at …
|
Which Six Companies Are in Michael King’s Oncology Wheelhouse?
Trefis I think chemotherapy will continue be used and Rituxan (rituximab; administered via infusion) will continue to be used, but now the new drugs will begin to be used in the relapse/refractory patient population. Researchers are also starting to see … |
TG Therapeutics: Biotech Suitors Not Waiting For Clinical ResultsSeeking AlphaGilead Science (GILD) acquired Calistoga Pharmaceutics in 2011 before completion of Phase II studies as a single agent in patients with refractory indolent non-hodgkins lymph…
|
Which Companies Are In Michael King’s Oncology Wheelhouse?
Seeking Alpha I think chemotherapy will continue be used and Rituxan [rituximab; administered via infusion] will continue to be used, but now the new drugs will begin to be used in the relapse/refractory patient population. Researchers are also starting to see … |
|
Which Six Companies Are in Michael King’s Oncology Wheelhouse?
InvestorIdeas.com (press release) I think chemotherapy will continue be used and Rituxan (rituximab; administered via infusion) will continue to be used, but now the new drugs will begin to be used in the relapse/refractory patient population. Researchers are also starting to see … |
Spectrum Pharmaceuticals Inc.Posted on:11 Jan 13PharmiWeb.com (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targe…
|
Which Six Companies Are in Michael King’s Oncology Wheelhouse?
Jutia Group I think chemotherapy will continue be used and Rituxan (rituximab; administered via infusion) will continue to be used, but now the new drugs will begin to be used in the relapse/refractory patient population. Researchers are also starting to see … |
Rituximab failed to improve survival after stem cell transplant for DLBCLHealioPatients with diffuse large B-cell lymphoma who were treated with rituximab after autologous stem cell transplantation experienced similar outcomes as those in an observatio…
|
Le rituximab cherche encore sa place dans la maladie de Sjörgen
Medscape France Paris, France — Le rituximab améliore l’état de santé global des patients atteints de syndrome de Sjörgen primitif à 6 semaines mais pas à 6 mois selon les résultats de l’étude randomisée TEARS présentée à l’occasion du 25e congrès français de … |
Clinical Oncology NewsAdjuvant Therapy Fails for High-Risk Soft Tissue SarcomaClinical Oncology NewsIn most oncology patients, one can get cyclophosphamide-doxorubicin or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) any…